This expanded FDA clearance adds a meaningful product capability to AYON, potentially accelerating adoption in the surgical aesthetics market. Monitor the limited commercial launch phase for early adopter feedback and any subsequent revenue guidance updates in upcoming quarterly filings.
Price Chart
Executive Summary
Apyx Medical received expanded FDA 510(k) clearance for its AYON Body Contouring System to include power liposuction, adding a second advanced liposuction modality. The company plans a limited commercial launch to refine training and customer experience before scaling. No financial figures or revenue impact were disclosed in the filing.
Key Facts
- Expanded FDA 510(k) clearance for AYON Body Contouring System to include power liposuction
- Power liposuction uses a reciprocating cannula to enhance fat removal efficiency and reduce surgeon effort and OR time
- Company plans a limited commercial launch with early adopters before scaling commercial adoption
- Original 510(k) for power liposuction label expansion was filed in October 2025
- AYON is an all-in-one platform integrating fat removal, closed loop contouring, electrosurgical capabilities, and Renuvion tissue contraction
Financial Impact
No financial figures disclosed in the filing. The expanded clearance is expected to drive greater market demand for AYON, but no revenue or cost estimates were provided.
Risk Factors
- Limited commercial launch may not scale as expected if early adopter feedback is negative
- Competitive response from other body contouring systems could limit market share gains
- No financial guidance or revenue projections were provided, making near-term impact uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-016000 |
| Exhibit: ex_959721.htm | 0001437749-26-016000 |
| Document: 0001437749-26-016000-index-headers.html | 0001437749-26-016000 |
| Document: 0001437749-26-016000-index.html | 0001437749-26-016000 |
| Document: 0001437749-26-016000.txt | 0001437749-26-016000 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $2.41 | awaiting T+20 | — | $2.46 (+2.07%) |
Aug 7, 2026 11w ago | 8-K | $3.46 $3.05 | ▼ −11.85% | ▼ −10.94% | $2.46 (−28.90%) |
May 21, 2026 22w ago | 8-K | $4.13 $3.95 | ▼ −4.36% | ▼ −2.94% | $2.46 (−40.44%) |
May 21, 2026 22w ago | Press Release | $4.25 $4.04 | ▼ −4.94% | ▼ −5.27% | $2.46 (−42.12%) |
May 14, 2026 23w ago | 8-K | $4.36 $4.69 | ▲ +7.57% | ▲ +8.43% | $2.46 (−43.58%) |
May 11, 2026 24w ago | 8-K | $3.92 $4.86 | ▲ +23.98% | ▲ +24.28% | $2.46 (−37.24%) |
Apr 23, 2026 26w ago | Press Release | $3.80 $3.79 | ▼ −0.26% | ▼ −4.90% | $2.46 (−35.26%) |
Mar 10, 2026 32w ago | Press Release | $3.45 $3.81 | ▲ +10.43% | ▲ +10.59% | $2.46 (−28.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers